An example of novel therapeutic agents successfully targeting specific KRAS mutations is sotorasib, the first FDA-approved drug for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC) [30]. Here, KRAS is linked to non-small cell lung carcinoma.